Recursion Pharmaceuticals
5 statements across 1 episodes · 3 bullish · 0 bearish · 1 people on the record · first statement Apr 17, 2017 by Chris Gibson · said 32 times in 3 episodes since 2017 · across every show →
Mentions by year
brought up most by Nathan Latka (22), Chris Gibson (10)
tap a year for its mentions
2017 32 mentions in 3 episodes 11 per episode
- 632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson
- 631: Saleswise Raises $3m, Launches Product, Helping 12 Customers Deveop Better Relationships with Their Data with CEO Gregg Freishtat
- 633: Pipefy $2.6M Raised, $50k MRR, Helping 400 Customers Organize Processes with CEO Alessio Alionco
- every mention in 2017, scene by scene →
Everything said about Recursion Pharmaceuticals, oldest first
Apr 17, 2017 positive
Apr 17, 2017 positive
Gibson: Recursion partnered with Sanofi Genzyme to repurpose shelved drugs
“We've announced, for example, a partnership with Sanofi Genzyme, and in that particular case, we have drugs that, that they spent decades working on in many cases, and those drugs never ended up making it to patients, not because they're bad drugs, just becaus…”
Apr 17, 2017 bullish
Apr 17, 2017
Gibson: Recursion raised $19M in equity and $5-6M in non-dilutive grants
“Yeah, we've raised about nineteen million dollars in, in equity financing, and then another five or six million in sort of non-dilutive funds from small business grants from the NIH, and then a number of private foundations as well.”
Apr 17, 2017 neutral
Gibson: Traditional life sciences investors value single assets over platforms
“So we are a platform company, and in our particular space, that's in life sciences, that's actually not the language that people speak in terms of value. They speak in terms of assets. And so that was one of the real challenges for us in terms of raising money…”